Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Cleveland BioLabs Licenses Cancer Drug to Zhejiang Hisun

publication date: Sep 10, 2009

Cleveland BioLabs has granted an exclusive China license for Protectan CBLB612, an investigational cancer drug, to Zhejiang Hisun Pharmaceutical Co. Ltd. In animal studies, the drug has been shown to stimulate hematopoietic stem cell proliferation and mobilization. Cleveland BioLabs says the drug shows promise as a treatment for the negative side-effects of chemotherapy. More details...

Stock Symbols: (NSDQ: CBLI) (SHSE: 600267)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital